| Title |
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, December 2012
|
| DOI | 10.1007/s10549-012-2382-0 |
| Pubmed ID | |
| Authors |
Markus Wallwiener, Andreas Daniel Hartkopf, Irène Baccelli, Sabine Riethdorf, Sarah Schott, Klaus Pantel, Frederik Marmé, Christof Sohn, Andreas Trumpp, Brigitte Rack, Bahriye Aktas, Erich-Franz Solomayer, Volkmar Müller, Wolfgang Janni, Andreas Schneeweiss, Tanja Natascha Fehm |
| Abstract |
The detection of circulating tumor cells (CTCs) in the peripheral blood of metastatic breast cancer (MBC) patients is an independent marker of prognosis. This large prospective multicenter study aimed to assess the impact of CTCs on overall survival (OS) and progression free survival (PFS) in patients with predefined molecular subgroups of MBC. To this end, 468 MBC patients were divided into three subgroups based on immunohistochemical staining of the primary tumor: (1) hormone receptor-positive/HER2-negative (HorR+/HER2-), (2) HER2-positive (HER2+), and (3) HorR-negative/HER2-negative (HorR-/HER2-) patients. CTC status (<5 CTCs/7.5 ml blood (CTC-negative) vs. ≥5 CTCs/7.5 ml blood (CTC-positive)) was determined using the CellCearch(®) system before patients started a new line of therapy. At baseline, 205 (42 %) patients were CTC-positive. On multivariate analysis, CTC-positivity was an independent prognostic factor for shorter PFS and OS. In HorR+/HER2- patients, median PFS [95 % CI] of CTC-negative versus CTC-positive patients was 8.60 [5.93-11.27] versus 4.33 [3.29-5.38] months (p < 0.001), in HER2+ patients 7.60 [5.40-9.79] versus 6.60 [4.20-9.00] months (p = 0.477) and in HorR-/HER2- patients 5.83 [5.09-6.78] versus 3.05 [1.81-4.29] months (p < 0.001), respectively. Median OS [95 % CI] of CTC-negative versus CTC-positive patients was as follows: not reached by either in the HorR+/HER2- subgroup (p < 0.001), not reached versus 18.07 [11.10-25.05] months (p = 0.001) in the HER2+ subgroup, and not reached versus 8.57 [4.07-13.07] months in the HorR-/HER2- subgroup (p = 0.001). In conclusion, our results strongly confirm the independent prognostic value of CTC enumeration in MBC patients. In contrast to recent reports, there was no association between primary tumor-based molecular subgroups and the impact of CTC status on OS. Hence, CTC status may help to identify patients who require aggressive therapy, especially among those with triple-negative MBC. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 1 | 25% |
| Romania | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| India | 1 | 1% |
| Unknown | 81 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 25% |
| Student > Ph. D. Student | 15 | 18% |
| Other | 8 | 10% |
| Student > Bachelor | 6 | 7% |
| Student > Doctoral Student | 4 | 5% |
| Other | 12 | 14% |
| Unknown | 17 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 35% |
| Agricultural and Biological Sciences | 15 | 18% |
| Biochemistry, Genetics and Molecular Biology | 11 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Chemical Engineering | 2 | 2% |
| Other | 4 | 5% |
| Unknown | 20 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2013.
All research outputs
#12,750,257
of 22,691,736 outputs
Outputs from Breast Cancer Research and Treatment
#2,753
of 4,618 outputs
Outputs of similar age
#151,366
of 280,171 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#32
of 48 outputs
Altmetric has tracked 22,691,736 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,618 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,171 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.